Cytotoxic Chemotherapy and CD4+ Effector T Cells: An Emerging Alliance for Durable Antitumor Effects
Abstract
Standard cytotoxic chemotherapy can initially achieve high response rates, but relapses often occur in patients and represent a severe clinical problem. As increasing numbers of chemotherapeutic agents are found to have immunostimulatory effects, there is a growing interest to combine chemotherapy and immunotherapy for synergistic antitumor effects and improved clinical benefits. Findings from recent studies suggest that highly activated, polyfunctional CD4+ effector T cells have tremendous potential in strengthening and sustaining the overall host antitumor immunity in the postchemotherapy window. This review focuses on the latest progresses regarding the impact of chemotherapy on CD4+ T-cell phenotype and function and discusses the prospect of exploiting CD4+ T cells to control tumor progression and prevent relapse after chemotherapy.Citation
Clin Dev Immunol. 2012 Feb 6; 2012:890178ae974a485f413a2113503eed53cd6c53
10.1155/2012/890178
Scopus Count
Related articles
- Polyfunctional CD4⁺ T cells are essential for eradicating advanced B-cell lymphoma after chemotherapy.
- Authors: Ding ZC, Huang L, Blazar BR, Yagita H, Mellor AL, Munn DH, Zhou G
- Issue date: 2012 Sep 13
- Activated CD4+ T cells dramatically enhance chemotherapeutic tumor responses in vitro and in vivo.
- Authors: Radfar S, Wang Y, Khong HT
- Issue date: 2009 Nov 15
- Does chemotherapy augment anti-tumor immunotherapy by preferential impairment of regulatory T cells?
- Authors: Zhang L, Dermawan KT, Jin ML, Xiong SD, Chu YW
- Issue date: 2008 Nov
- Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity.
- Authors: Ménard C, Martin F, Apetoh L, Bouyer F, Ghiringhelli F
- Issue date: 2008 Nov
- Periodically Pulsed Immunotherapy in a Mathematical Model of Tumor, CD4<sup>+</sup> T Cells, and Antitumor Cytokine Interactions.
- Authors: Wei HC, Yu JL, Hsu CY
- Issue date: 2017